Kymera Therapeutics, Inc. (KYMR)
NASDAQ:KYMR
Want to see KYMR full AI Analyst Report?
KYMR Stock Chart & Stats
$87.71
-$0.34(-0.84%)
At close: 4:00 PM EST
$87.71
-$0.34(-0.84%)
Day’s Range― - ―
52-Week Range$36.65 - $103.00
Previous CloseN/A
Volume48.51K
Average Volume (3M)589.45K
Market Cap
$7.44B
Enterprise Value$7.33B
Total Cash (Recent Filing)$650.93M
Total Debt (Recent Filing)$80.47M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Jul 31, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding82,257,590
10 Day Avg. Volume717,401
30 Day Avg. Volume589,445
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue142.45
Enterprise Value/Gross Profit142.45
Enterprise Value/Ebitda-23.95
Forecast
1Y Price Target
$119.22Price Target Upside35.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.48
Revenue Forecast (FY)$82.81M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetKymera’s very low debt-to-equity (~0.05) and sizable equity base provide durable financial flexibility to fund multi-year clinical programs and absorb development setbacks. Low leverage reduces refinancing and interest risk, preserving capacity to invest in R&D and partnerships over the medium term.
Strengthening Revenue TrendMeaningful TTM revenue growth (~+31% to ~$51.5M) indicates improving execution on collaboration and licensing arrangements. Growing non-product revenue validates external interest in the platform, supports funding of programs, and can reduce net cash needs if sustained through milestone and research payments.
Governance Update Reduces Litigation UncertaintyBy updating bylaws to centralize securities claims in federal court, Kymera reduces jurisdictional fragmentation and potential inconsistent rulings. This governance change improves predictability in litigation outcomes and lowers legal risk over time, which supports investor confidence and long-term governance stability.
Bears Say
Heavy Operating Cash BurnSustained negative operating cash flow and large negative free cash flow (~-$244M TTM) erode runway and force recurring external financing or partnership monetization. Persistent high burn constrains strategic flexibility, increases dilution risk, and makes long-term program funding contingent on capital markets or deals.
Large Recurring Net LossesVery large net losses (~$315M TTM) and deeply negative margins reflect that R&D and operating costs far outpace current revenue. Unless clinical and regulatory progress converts to partnered or product revenue, losses are likely to persist, pressuring returns and necessitating ongoing capital raises.
Clinical-stage, No Product RevenueAs a clinical-stage biotech with no marketed therapies, Kymera’s cash flow depends on collaborations, milestones, and financing. This creates a binary development risk profile and revenue volatility, leaving the company exposed to trial outcomes and partner decisions that materially affect long-term sustainability.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $36.65 and its highest was $103.00 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $7.44B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is Jul 31, 2026 which is in 40 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Apr 30, 2026. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.881 by $0.171.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 82,257,590 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.881. Following the earnings report the stock price went down -0.54%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$119.22 (35.93% Upside)
$119.22 (35.93% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 104.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $317.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.72%
12-Months-Change
Fundamentals
Return on Equity
-25.02%
Trailing 12-Months
Asset Growth
81.75%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum (notably KT-621 and KT-579), significant balance sheet strength (raised ~ $1B; $1.6B year-end cash) and multiple high-value collaborations, all supporting an ambitious development plan. Headwinds include elevated R&D spend (adjusted cash R&D +16% QoQ), limited current revenue, translational/measurement complexity for IRF5, and multi-year timelines to pivotal readouts and potential approvals. Overall, the positives—compelling early clinical data, IND/Phase I starts, partner validation and a multi-year cash runway—outweigh the noted operational and timing risks.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$119.22
▲(35.93% Upside)
Technical Analysis
Protagonist Therapeutics
―
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
12.36% Insiders
33.25% Mutual Funds
14.41% Other Institutional Investors
26.63% Public Companies and
Individual Investors